Zenas BioPharma (ZBIO) Cash from Investing Activities (2024 - 2026)

Zenas BioPharma's Cash from Investing Activities history runs 3 years deep, the most recent figure standing at $31.6 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 136.64% year-over-year to $31.6 million; the TTM figure through Mar 2026 stood at -$134.0 million (down 14.72% YoY), while the FY2025 annual figure was -$251.9 million, down 724.45% from the prior year.
• Cash from Investing Activities was $31.6 million for Q1 2026 at Zenas BioPharma, up from -$93.4 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $40.0 million in Q3 2025 to a low of -$112.3 million in Q2 2025.
• Historically, Cash from Investing Activities has averaged -$27.9 million across 3 years, with a median of -$3.7 million in 2024.
• Biggest YoY gain for Cash from Investing Activities was 249.64% in 2025; the steepest drop was 392054.55% in 2025.
• A 3-year view of Cash from Investing Activities shows it stood at -$3.7 million in 2024, then slumped by 2399.71% to -$93.4 million in 2025, then surged by 133.86% to $31.6 million in 2026.
• The last three Cash from Investing Activities figures came in at $31.6 million (Q1 2026), -$93.4 million (Q4 2025), and $40.0 million (Q3 2025), per Business Quant data.